The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis
Open accessAbstract
OBJECTIVES: Linaclotide and plecanatide are guanylate cyclase-C (GCC) agonists for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Our objective is to evaluate the efficacy and tolerability of GCC agonists based on data from multiple randomized controlled trials (RCTs). METHODS: We searched PubMED, EMBASE, Cochrane databases, clinicaltrials.gov, major conference abstracts, Food and Drug Administration (FDA) websites, and United States Securities and Exchange Commission filings of drug sponsors to identify RCTs of CIC or IBS-C patients. We assessed efficacy based on FDA-approved composite responder endpoints, diarrhea as an adverse event, and study withdrawal owing to diarrhea for each therapy. Trial results were pooled using DerSimonian and Laird random effects model of meta-analysis and exact logistic regression when appropriate with 95% confidence intervals. Meta-regression was performed to compare outcomes between therapies adjusting for placebo event rate. RESULTS: Eight linaclotide trials (five CIC; three IBS-C) and seven plecanatide trials (four CIC; three IBS-C) evaluating 10,369 patients met inclusion criteria. FDA publications documented that different definitions for diarrhea were used in linaclotide vs. plecanatide trials. Both drugs were efficacious in treating CIC (linaclotide 72 μg (Odds ratio (OR)=3.11, 95% CI 1.81-5.34); linaclotide 145 μg (OR=3.25, 2.15-4.91); plecanatide 3 mg (OR=1.99, 1.57-2.51)) and IBS-C (linaclotide 290 μg (OR=2.43, 1.48-3.98); plecanatide 3 mg (OR=1.87, 1.47-2.38); plecanatide 6 mg (OR=1.92, 1.48-2.48)). Diarrhea occurred in excess of placebo in treating CIC (linaclotide 72 μg (OR=3.07, 1.97-4.77); linaclotide 145 μg (OR=3.70, 2.69-5.10); plecanatide 3 mg (OR=3.86, 1.83-8.12)) and IBS-C (linaclotide 290 μg (OR=8.02, 5.20-12.37); plecanatide 3 mg (OR=5.55, 1.62-19.00); plecanatide 6 mg (OR=4.13, 1.57-10.83)). Based on meta-regression, there were no statistically significant differences between therapies in odds ratios for efficacy, diarrhea, or diarrhea-related study withdrawals. CONCLUSIONS: Both linaclotide and plecanatide demonstrate similar efficacy and tolerability in treating IBS-C and CIC. No differences in odds of diarrhea were seen between linaclotide and plecanatide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of linaclotide might be associated with diarrhea leading to discontinuation or dose reduction; however, this was not very common (in one study, 4.7% discontinued the medication because of diarrhea). 68,69”
From American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation (2023) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Participants treated with plecanatide might have higher rates of reported diarrhea leading to treatment discontinuation (RR 5.39, 95% CI 2.40-12.11), 27 more per 1,000 (from 9 to 69 more).”
From American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation (2023) · cites this paper as [68]
Experimental — accuracy not yet measuredIn the citing paper
“Secretory mechanisms are common therapeutic targets94, 95 of medications used to treat FGIDs.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Chey, W. D., Lembo, A. J., Lavins, B. J., Shiff, S. J., Kurtz, C. B., Currie, M. G., MacDougall, J. E., Jia, X. D., Shao, J. Z., Fitch, D. A., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.254 · Cited by 463
Rao, S. S. C., Lembo, A., Shiff, S., Lavins, B., Currie, M., Jia, X., Shi, K., Macdougall, J. E., Shao, J. Z., Eng, P., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.255 · Cited by 394
Two randomized trials of linaclotide for chronic constipation
Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010863 · Cited by 373
Health‐related quality of life among persons with irritable bowel syndrome: a systematic review
El‐Serag, H. B., Olden, K. W., & Bjorkman, D. J. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01290.x · Cited by 305
Efficacy of Linaclotide for Patients With Chronic Constipation
Lembo, A. J., Kurtz, C. B., MacDougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., Jeglinski, B. I., & Johnston, J. M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.050 · Cited by 237
Busby, R. W., Bryant, A. P., Bartolini, W. P., Cordero, E. A., Hannig, G., Kessler, M. M., Mahajan‐Miklos, S., Pierce, C. M., Solinga, R. M., Sun, L. J., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.019 · Cited by 236
Flagged first, then by citations
Research works printed but not linked: 3
- 2012, Med Lett Drugs T, her, 54, 91
- Hanes, 2016, Clinical review (Application Number 208745Orig1s000)., US Food Drug Adm, 140, 140
- Wynn, 2012, Clinical review (Application Number 202811Orig1s000)., US Food Drug Adm, 169, 169
Cited by
Sorted by citations
Items 101–119 of 119
Alsolami, A. A. (2023) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/19xy8dgjwy · Cited by 1
How to meet the challenges of managing patients with IBS
Villalon-Gomez (2021) · The Journal of Family Practice · doi:10.12788/jfp.0299 · Cited by 1
Pohl, D., Vavricka, S. R., Fox, M. R., Madisch, A., Studerus, D., Wiesel, P. H., Heinrich, H. S., Linas, I., Schoepfer, A. M., Schwizer, A., et al. (2023) · Praxis · doi:10.1024/1661-8157/a003988 · Cited by 1
Sierra-Arango, F., & Gómez, D. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0199-0
Blair, H. A. (2018) · Drugs & Therapy Perspectives · doi:10.1007/s40267-018-0579-y
Black, C. J. (2021) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Gastrointestinal Complications of Neuromuscular Disorders
Ismail, M. K., & Shrestha, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00004-4
Dharmarajan, T. S., Widjaja, D., & Pitchumoni, C. S. (2020) · Springer eBooks · doi:10.1007/978-3-319-90761-1_45-1
Frieling, T., & Keller, J. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-23847-5.00023-5
Shao, Y.-S., Xie, M., & Lu, R. (2022) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v30.i10.458
Abdominal pain syndrome in patients with irritable bowel syndrome: features of selection of therapy
Pakhomova, I. G. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-360
Frieling, T., & Keller, J. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21005-1.00024-x
Sharma, C., & Badyal, D. K. (2024) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_3_24
Pharmacotherapy for Irritable Bowel Syndrome with Constipation
Inamori, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-8410-3_12
28/w mit chronischen Bauchschmerzen und Verstopfung
Jasper, D. (2025) · Die Gastroenterologie · doi:10.1007/s11377-025-00857-4
New Pharmacologic Treatments in Pediatric Neurogastroenterology
Cohen, A., & Wheeler, J. C. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.02.007
Akram, U., Ain, H. U., Ahmed, S., Fatima, E., Raza, M. A., Ahmad, E., Ashraf, H., Bharadwaj, H. R., Asif, U., Chaudhary, A. J., et al. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003115
Zhou, Z., Li, Y., Tu, Y., He, M., Liao, D., He, Z., 刘志仁, Li, B., 周祖刚, & 艾双春 (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761301
Li, S. Y., Wei, H., Wang, J., Su, X. Y., Wu, Q., Wang, J., Peng, P., & Qin, M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1833539
Metadata
- Authors
- Shah, E. D., Kim, H. M., & Schoenfeld, P.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Schoenfeld, Philip
- Venue
- American Journal of Gastroenterology
- Published
- 2018-03
- Volume
- 113
- Issue
- 3
- Pages
- 329-338
- ISSN
- 0002-9270 (ISSN-L)
- PMC
- PMC7213047
- OpenAlex
- W2789261715
- Cited by
- 119
- References
- 28
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 8 · 2023: 17 · 2022: 13 · 2021: 26 · 2020: 16 · 2019: 12 · 2018: 14
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Ironwood Pharmaceuticals, Incorporated
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK084208, T32DK062708)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- guanylate cyclase-C agonist, linaclotide, plecanatide, irritable bowel syndrome with constipation, chronic idiopathic constipation, diarrhea, drug tolerability, drug efficacy, meta-regression
- MeSH terms
- Guanylyl Cyclase C Agonists, Chronic Disease, Constipation, Diarrhea, Humans, Peptides, Randomized Controlled Trials as Topic, Irritable Bowel Syndrome, Natriuretic Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
